This Month in Genetics  by Garber, Kathryn B.
EDITORS’ CORNER
This Month in Genetics
Kathryn B. Garber1,*Congratulations, It’s a Genome
Years of development were needed for bringing to fruition
noninvasive prenatal testing via cell-free fetal DNA. The
tests currently on the market screen only for the common
trisomies but are based on high-throughput DNA se-
quencing and could therefore be expanded to include
further analyses. Kitzman et al. recently published their
attempt at whole-genome sequencing of a fetus with
the use of cell-free fetal DNA, and their paper highlights
some of the challenges of this task. With a focus on
single-nucleotide variants, the researchers used whole-
genome sequence information from both parents in
conjunction with the cell-free DNA in plasma in order to
construct the fetal genome. A major challenge with the
analysis is the identification of the transmitted maternal
allele given that both maternal alleles are present in the
plasma sample. The authors tackled this by constructing
whole-genome fosmid libraries of the mother’s genome
and by using these libraries to generate haplotype-phased
sequences. They used the relative abundance of these
haplotypes in the maternal plasma to infer which allele
was transmitted to the fetus. Although far from perfect at
this point, this work is another example of the rapid
progression of genomic technologies and should engender
discussions concerning the use of fetal genome sequencing
in a clinical setting.
Kitzman et al. (2012). Sci Transl Med. 4, 137ra76.
Phase 2 Trial for Familial Hypercholesterolemia
Therapy
Statins such as Lipitor and Crestor are used for reducing
cholesterol levels by inhibiting cholesterol synthesis in
the liver. A nice side effect of these drugs is that they
increase the expression of the low density lipoprotein
(LDL) receptor, which can then clear more LDL out of
the bloodstream. The statins have proved to be tremen-
dously successful at managing high cholesterol levels in
general populations, but they don’t do as well in patients
with familial hypercholesterolemia (FH); these individuals’
LDL receptors are dysfunctional, and residual LDL levels in
statin-treated FH patients still leave these individuals at
high risk of coronary artery disease. One potential target
for FH therapy is PCSK9. This protein binds to the LDL
receptor and directs it for degradation. After a phase 2
double-blind trial for patients with FH, Stein et al. recently
reported that a monoclonal antibody against PCSK9 is1Department of Human Genetics, Emory University School of Medicine, Atlan
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the interaction between PCSK9 and the LDL receptor and
thereby enhances receptor activity. Blocking the interac-
tion is predicted to augment the effect of statin therapy,
and indeed it does. Of statin-treated individuals who
were given subcutaneous injection of the antibody every
two weeks, 94% achieved the goal of 2.6 mmol/l of LDL
cholesterol.
Stein et al. (2012). Lancet. Published online May 26, 2012.
10.1016/S0140-6736(12)60771-5.
Sijbrands. (2012). Lancet. Published online May 26, 2012.
10.1016/S0140-6736(12)60814-9.
Playing Chicken with Alzheimer Disease
Variation at the APOE locus is the major known contrib-
utor to genetic susceptibility to Alzheimer disease, and it
also influences the risk of cardiovascular disease. ApoE in
mice is needed for the maintenance of the blood-brain
barrier, so Bell et al. recently sought to understand the
APOE-Alzheimer link by studying the effect on the
blood-brain barrier of various human isoforms of APOE
in mice. Targeted replacement of Apoe in mice with the
human Alzheimer risk allele APOE4 disrupts the blood-
brain barrier in a pathway that involves cyclophilin,
nuclear factor kB (NFkB), and matrix metalloproteinase 9.
This pathway is not stimulated by the APOE3 or APOE2
alleles, which are associated with a lower risk of Alzheimer
disease. There has been a chicken-egg argument con-
cerning vascular defects and neuronal changes in the
Alzheimer brain. Because mice expressing APOE4 exhibit
vascular defects prior to neuronal dysfunction, Bell et al.
think they’ve discovered which actually comes first. If
the mouse model recapitulates the human situation,
therapies targeting this NFkB-mediated pathway could
moderate the neuronal changes associated with APOE4.
Bell et al. (2012). Nature 485, 512–516.
Blame It on the CNV
You kind of have to hate the person who can eat anything
and remain thin as a rail, right? But why are some people
lucky enough to have a ‘‘quick metabolism’’ when others
have to watch everything they eat? It’s easy to say it’s
just ‘‘good genetics’’ or to blame the size of your hips on
your mother, but we are only beginning to understand
the specific genetic variation that contributes to pheno-
types such as obesity and metabolic syndrome. Sometimesta, GA 30322, USA
y of Human Genetics. All rights reserved.
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rare examples can provide a springboard into explorations
into the common forms of a phenotype, and that is the
case for recent work by Lacaria et al., who assessed the
effects of copy-number variation at chromosome 17p11
on metabolism. Deletion and duplication of this region
cause Smith-Magenis and Potocki-Lupski syndromes,
respectively. The authors recently described highly pene-
trant and opposite metabolic phenotypes associated
with a deletion versus a duplication of the region syntenic
to 17p11 in mice. Compared with their littermates, mice
with the deletion had higher weights and fat content
and reduced sensitivity to insulin, whereas the duplication
protected against these features, which are reminiscent of
metabolic syndrome. Over 40 genes are included in this
variable region, and the metabolic phenotypes have so
far not been attributed to a single gene. However, this at
least defines a relatively small portion of the genome that
has a big effect on weight control, regardless of the genetic
background on which it occurs. It remains to be seen
whether milder genetic variation in this region is associ-
ated with obesity in the general population, but this
work does provide a candidate region to be explored.
Lacaria et al. (2012). PLoS Genet. 8, e1002713.4 The American Journal of Human Genetics 91, 3–4, July 13, 2012Shank Redemption
You mess with the synapse, you get autism. At least it
seems that way because mutations in a variety of genes
for these proteins have been found in patients with autism.
To understand this better, two groups recently character-
ized mice with deletions within the gene for the synaptic
protein ProSAP1/Shank2. Although both groups of re-
searchers did similar assays and both groups of mice do
have some features reminiscent of autism, the back-to-
back papers are a journal club in the making in that their
results are not fully concordant. Whereas Won et al. found
reduced NMDA-receptor function in mice homozygous for
a Shank2 deletion, Schmeisser et al. suggested that NMDA
receptor function was enhanced.Won et al. did go one step
further by manipulating the activity of NMDA receptors
and demonstrating improvements in the social interac-
tions of their mice, thereby pharmacologically redeeming
their Shank-mediated deficits. The differences between
the two papers still need to be teased out, but they do
strengthen the tie between autism and the scaffold
proteins at the excitatory synapse.
Schmeisser et al. (2012). Nature 486, 256–260.
Won et al. (2012). Nature 486, 261–265.
